Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract CancersRachna T. Shroff, Mitesh J. Borad, Milind Javle et al.|JAMA Oncology|2019Cited by 472
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 studyMilind Javle, Ghassan K. Abou‐Alfa, Sameek Roychowdhury et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 423
Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic CholangiocarcinomaMitesh J. Borad, John D. Carpten|PLoS Genetics|2014Cited by 341
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancerJ.E. Berchuck, Love Goyal, Francesco Facchinetti et al.|Annals of Oncology|2022Cited by 138
Circulating Tumor DNA Profiling of Advanced Biliary Tract CancersKabir Mody, Mitesh J. Borad, Daniel H. Ahn et al.|JCO Precision Oncology|2019Cited by 86